1000s of practice questions to help you prepare for the 2025 GPhC registration assessment, including extended matching answer, single best answer and calculations.
NICE recommends ‘breakthrough’ therapy for blood cancer
Belantamab mafodotin combination therapy is a second-line treatment option for multiple myeloma that could benefit around 1,500 people....
MHRA publishes ‘world first decentralised manufacturing guidance
The guidance will inform the manufacture of medicines with a short shelf-life or highly personalised medicines at sites within or...
Yellow Card reporting in East London NHS Foundation Trust
...
NICE recommends mirikizumab as a treatment option for Crohn’s disease
Mirikizumab (Omvoh; Eli Lilly), which is already licensed to treat ulcerative colitis but at a lower dose, is now recommended...
Pharmacy students included for first time in NHS Learning Support Fund travel expense scheme
The travel and dual accommodation expenses provision of the NHS Learning Support Fund will cover some costs related to students...
Grasping new opportunities to work in partnership with the pharmaceutical industry
The development of a pharmacy-led maintenance and reliever therapy programme has shown success in Leeds, where there are high numbers...
Copyright © 2025 Royal Pharmaceutical Society
Designed and built by Redwing Interactive
